Literature DB >> 23931952

Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson's disease.

Peter Jenner1.   

Abstract

Motor fluctuations (wearing off) and motor complications (dyskinesia) are common features of the long-term treatment of Parkinson's disease (PD). The basis of both is considered to be a reflection of the progression of neuronal degeneration, coupled with the nature of drug treatment used to control motor symptoms. The concept of continuous dopaminergic stimulation has been used to explain both the onset of wearing off and dyskinesia and their avoidance through pharmacologic manipulation. This review focuses on using with the transdermal dopamine agonist, rotigotine, for continuous dopaminergic drug delivery in the treatment of PD.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug delivery; Dyskinesia; Parkinson's disease; Rotigotine; Wearing off

Mesh:

Substances:

Year:  2013        PMID: 23931952     DOI: 10.1016/j.ncl.2013.04.010

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  12 in total

1.  Continuous quantitative monitoring of physical activity in Parkinson's disease patients by using wearable devices: a case-control study.

Authors:  Guoen Cai; Yujie Huang; Shan Luo; Zhirong Lin; Houde Dai; Qinyong Ye
Journal:  Neurol Sci       Date:  2017-06-28       Impact factor: 3.307

2.  Baseline cognitive profile is closely associated with long-term motor prognosis in newly diagnosed Parkinson's disease.

Authors:  Seok Jong Chung; Han Soo Yoo; Hye Sun Lee; Yang Hyun Lee; KyoungWon Baik; Jin Ho Jung; Byoung Seok Ye; Young H Sohn; Phil Hyu Lee
Journal:  J Neurol       Date:  2021-05-04       Impact factor: 4.849

3.  Cilostazol Mediated Nurr1 and Autophagy Enhancement: Neuroprotective Activity in Rat Rotenone PD Model.

Authors:  Shireen A Hedya; Marwa M Safar; Ashraf K Bahgat
Journal:  Mol Neurobiol       Date:  2018-02-10       Impact factor: 5.590

4.  RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease.

Authors:  Katelin E Ahlers-Dannen; Mackenzie M Spicer; Rory A Fisher
Journal:  Mol Pharmacol       Date:  2020-02-03       Impact factor: 4.436

5.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

Review 6.  Improving the Delivery of Levodopa in Parkinson's Disease: A Review of Approved and Emerging Therapies.

Authors:  Daniele Urso; K Ray Chaudhuri; Mubasher A Qamar; Peter Jenner
Journal:  CNS Drugs       Date:  2020-11-04       Impact factor: 5.749

Review 7.  Non-oral Continuous Drug Delivery Techniques in Parkinson's Disease: For Whom, When, and How?

Authors:  Jonathan Timpka; Tove Henriksen; Per Odin
Journal:  Mov Disord Clin Pract       Date:  2016-03-24

8.  The Comparative Efficacy of Non-ergot Dopamine Agonist and Potential Risk Factors for Motor Complications and Side Effects From NEDA Use in Early Parkinson's Disease: Evidence From Clinical Trials.

Authors:  Chunxiao Wu; Hongji Guo; Yingshan Xu; Luping Li; Xinyu Li; Chunzhi Tang; Dongfeng Chen; Meiling Zhu
Journal:  Front Aging Neurosci       Date:  2022-04-22       Impact factor: 5.750

9.  LSVT-BIG Improves UPDRS III Scores at 4 Weeks in Parkinson's Disease Patients with Wearing Off: A Prospective, Open-Label Study.

Authors:  Tatsuya Ueno; Megumi Sasaki; Haruo Nishijima; Yukihisa Funamizu; Tomoya Kon; Rie Haga; Akira Arai; Chieko Suzuki; Jin-Ichi Nunomura; Masayuki Baba; Masahiko Tomiyama
Journal:  Parkinsons Dis       Date:  2017-02-01

10.  The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis.

Authors:  Peter A LeWitt; Werner Poewe; Lawrence W Elmer; Mahnaz Asgharnejad; Babak Boroojerdi; Frank Grieger; Lars Bauer
Journal:  Clin Neuropharmacol       Date:  2016 Mar-Apr       Impact factor: 1.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.